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Nigeria is Africa’s most 
populous nation, with 
approximately 189 
million people. Modern 
contraceptive services are 
underutilized in Nigeria, 
which has a modern 
contraceptive prevalence 
rate (mCPR) of 10 percent. 
The country’s low mCPR 
highlights the need for 
innovative programs to 
increase women’s access to 
contraceptive services.
In Nigeria, overall modern contraceptive use is very low, with just 10 percent 
of currently married women using a modern method. However, 60 percent of 
modern contraceptive services are obtained from private providers, including 
Patent and Proprietary Medicine (PPM) shops, which provide more than half of 
these private sector services. PPM shops are owned by Patent and Proprietary 
Medicine Vendors (PPMVs) licensed to sell patent or proprietary drugs. PPMVs 
sell a range of contraceptives including condoms, emergency contraceptive pills, 
refills of oral contraceptive pills, and intrauterine devices (with a referral). 
Injectable contraception is the most popular modern method in Nigeria, used by 
more than 30 percent of currently married modern contraceptive users. Current 
regulations do not permit PPMVs to sell or administer injectable contraceptives 
because they are not regarded as sufficiently trained to initiate hormonal 
contraceptives or to provide any type of injection. Instead, they can only refer 
clients to health facilities. Nevertheless, almost 13 percent of injectables are 
provided by PPM shops, according to the 2013 DHS.
Given this, it is an opportune time to generate evidence that can drive policy action 
to formally engage and train PPMVs in the provision of high quality progestin-only 
injectable contraceptive services as a key strategy to increase women’s access 
to contraception.
STUDY OBJECTIVES
The Evidence Project, in collaboration with the Federal Ministry of Health (FMOH), 
is conducting implementation research to:
1. Demonstrate the feasibility of PPMVs administering all forms of progestin-only 
injectable contraceptives, such as Depo Provera and Sayana® Press.
2. Understand women’s experiences using progestin-only injectable 
contraceptives, including the quality of care they receive when accessing 
services from PPMVs.
The FMOH also asked the Evidence Project to develop and coordinate training 
of PPMVs so that they have the necessary skills and information to sell, counsel, 
and refer for all contraceptive methods, as well as administer progestin-only 
injectable contraceptives.
The study is taking place in two phases. Phase one (November 2015 to December 
2016) was carried out in two states representing two geopolitical zones: Oyo in 
the south-west and Nasarawa in north-central Nigeria. In each state, four Local 
Government Areas (LGAs) were selected as study sites (two urban and two rural) 
for a total of eight LGAs. Phase two began in May 2017 at the request of and with 
funding from USAID/Nigeria to generate similar evidence from states, selected 
in consultation with local stakeholders, in the remaining four geopolitical zones, 
so that the evidence is nationally representative. The phase two study states 
include: Kaduna (north-west region), Ebonyi (south-east region), Cross River 
(south-south region), and Bauchi (north-east region).
ACTIVIT Y BRIEF
Strengthening the Role of Patent and Proprietary 
Medicine Vendors in the Provision of Injectable 
Contraception in Nigeria
THE PILOT INTERVENTION
PPMVs who participate in the study take part in a five-day 
training on FP counseling for all methods and on administration 
of progestin-only injectable contraceptives. The training covers 
screening and counseling clients interested in the injectable; 
intramuscular and subcutaneous injectable contraceptives 
and their administration; safe storage and proper disposal; 
reinjection procedures and instructions for clients , and what 
to do if an adverse event occurs. 
The research team has established new and strengthened 
existing relationships with many stakeholders, including the 
National Association of Patent and Proprietary Medicine Dealers 
(NAPPMED), which helped recruit PPMVs for phase one of the 
study, and the Pharmacy Council of Nigeria for phase two PPMVs. 
Other stakeholders include the FMOH and state Ministries of 
Health (SMOH) and implementing organizations that work with 
PPMVs, who review and refine training materials, participate 
in the training, and interpret the study’s findings. The team is 
working with local government health facilities in study LGAs 
to ensure the acceptance of referrals by PPMVs. Additionally, 
FMOH, SMOH, and LGA officials  are  involved in the planning, 
implementation, and training of PPMVs. The Society for Family 
Health (SFH) and DKT will be involved to reduce the likelihood 
of stock-outs of Depo Provera and Sayana® Press and ensure 
the availability of quality products. SFH and DKT are two of the 
main sources for private providers to purchase affordable family 
planning commodities in the private sector in Nigeria.
HOW THE DATA ARE BEING COLLECTED
Pre- and post-PPMV training surveys
The PPMVs complete pre- and post-training surveys to 
ascertain changes in knowledge and practices related to 
injectable contraceptives. Additionally, follow-up surveys are 
administered three, and nine months post-training to assess 
the PPMVs’ practices, knowledge and skills over time.
Monitoring/supervision of PPMVs
Teams of study investigators, FMOH, SMOH, LGA officials 
and PCN monitor activities of trained PPMVs through follow-
up meetings to identify and resolve implementation issues. 
The monitoring visits will track progress, challenges, and 
successes of implementation, as well as gather information 
on clients’ experience of adverse events. Involvement of the 
ministry stakeholders will also help them to see firsthand 
the PPMVs’ abilities with administration of injectables and 
potentially help with eventual policy change.
Client exit interviews and surveys
To obtain female clients’ perspectives, the researchers conduct 
exit interviews with progestin-only injectable contraceptive 
users who receive services from trained PPMVs. These users 
are also contacted for surveys at three, six, and nine months 
after their initial visit, enabling the assessment of continuation 
rates of progestin-only injectable contraceptive methods.
FOSTERING RESEARCH UTILIZATION
The research team has from the beginning of the study 
and will continue to engage key decision makers, such as 
the FMOH, SMOH and LGA health officials; utilize technical 
working groups to discuss emerging findings and lessons as 
the study progresses; and identify champions to promote the 
study findings to key stakeholders, such as health officials, 
NAPPMED, Pharmacy Council of Nigeria, FMOH, donors, NGOs, 
and so forth. In addition to regular meetings throughout the 
study to keep stakeholders informed of the progress and initial 
findings, a national dissemination meeting will be held with the 
key stakeholders to review and interpret the results and identify 
how they can be translated into policy. State-level meetings 
also will be held to share implementation successes and 
challenges related to PPMV delivery of injectable contraceptive 
services.
For more information, go to evidenceproject.popcouncil.org or contact Salisu Ishaku at sishaku@popcouncil.org
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Injectable Contraceptive Methods
There are two types of injectable hormonal contraceptives: 
those that are injected intramuscularly, like Depo Provera, 
and those that are injected subcutaneously, like Sayana® 
Press. In Nigeria, intramuscular injections were the only 
available option for women wishing to use injectable con-
traception until 2014, when Sayana® Press was introduced 
as a second safe and efficacious option. Sayana® Press 
comes as a single dose in a prefilled, sterile syringe, and 
is administered once every three months. It is packaged in 
the Uniject injection system with an autodisposable device 
that eliminates the need to prepare a needle and syringe. 
Because the injection is subcutaneous, the needle is small-
er and thus less painful.
